Products for Research Use Only

Degarelix (Standard)

CAT: 0804-HY-16168ARSize: InquireDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-16168ARSize:Inquire
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
CAS Number
214766-78-6
UNSPSC Description
Degarelix (Standard) is the analytical standard of Degarelix. This product is intended for research and analytical applications. Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix can be used for prostate cancer research[1].
Target Antigen
Apoptosis; GnRH Receptor
Type
Reference Standards
Related Pathways
Apoptosis;GPCR/G Protein
Field of Research
Cancer; Endocrinology
Assay Protocol
https://www.medchemexpress.com/degarelix-standard.html
Smiles
C[C@H](C(N)=O)NC([C@H]1N(C([C@H](CCCCNC(C)C)NC([C@H](CC(C)C)NC([C@@H](CC2=CC=C(NC(N)=O)C=C2)NC([C@H](CC3=CC=C(NC([C@H](CC(N4)=O)NC4=O)=O)C=C3)NC([C@H](CO)NC([C@@H](CC5=CC=CN=C5)NC([C@@H](CC6=CC=C(Cl)C=C6)NC([C@@H](CC7=CC=C8C=CC=CC8=C7)NC(C)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC1)=O
Molecular Weight
1632.26
References & Citations
[1]Rick FG, et al. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. Onco Targets Ther. 2013 Apr 16;6:391-402.|[2]Sakai M, et al. In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonistdegarelix on human prostate cell growth. PLoS One. 2015 Mar 26;10(3):e0120670.|[3]Broqua P, et al. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormoneantagonist: degarelix. J Pharmacol Exp Ther. 2002 Apr;301(1):95-102.|[4]Sonesson A, et al. Metabolite profiles of degarelix, a new gonadotropin-releasing hormone receptor antagonist, in rat, dog, and monkey. Drug Metab Dispos. 2011 Oct;39(10):1895-903.
Shipping Conditions
Room temperature